Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 5 Issue 11, November 2006

In This Issue

Top of page ⤴

Editorial

Top of page ⤴

News and Analysis

Top of page ⤴

News in Brief

Top of page ⤴

Patent Watch

Top of page ⤴

An Audience With

Top of page ⤴

From the Analyst's Couch

Top of page ⤴

Fresh from the Pipeline

    • Steven D. Gore
    • Carole Jones
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Opinion

  • Existing guidance for the validation of biomarkers is subjective and prone to bias resulting from stakeholder interests. Williams and colleagues describe an approach in which biomarkers could be qualified according to their 'cost-effectiveness' using a set of 'good practice' principles.

    • Stephen A. Williams
    • David E. Slavin
    • Christopher J. Webster
    Opinion
Top of page ⤴

Review Article

  • Phosphatidylinositol 3-kinase (PI3K)γ is an emerging target for the development of drugs with anti-inflammatory and/or cardioprotective activity. Rommel and colleagues review the biology of this key signalling molecule and discuss current efforts to develop selective PI3Kγ inhibitors.

    • Thomas Rückle
    • Matthias K. Schwarz
    • Christian Rommel
    Review Article
  • The potential market for obesity drugs is huge, and current therapies are limited by their side effects and modest efficacy. Cooke and Bloom provide insights into current anti-obesity strategies, with a focus gut peptides as a promising source for future obesity therapies.

    • Dunstan Cooke
    • Steve Bloom
    Review Article
  • Lead discovery is a major bottleneck in the pipeline for novel drugs for tropical diseases such as malaria. Nwaka and Hudson discuss how lead-discovery strategies based on highly integrated partnerships and networks involving academia and industry in industrialized and disease-endemic countries could increase the chances of success.

    • Solomon Nwaka
    • Alan Hudson
    Review Article
  • Animal models contribute to advancing our understanding of the pathophysiology of complex disorders and the preclinical assessment of therapeutics for these diseases. Van Dam and De Deyn review the major rodent models of Alzheimer's disease and evaluate their usefulness for drug discovery research

    • Debby Van Dam
    • Peter Paul De Deyn
    Review Article
Top of page ⤴

Careers and Recruitment

Top of page ⤴

Search

Quick links